Case report: Biocon’s breast cancer biosimilar gets green light

The Division Bench of the Delhi High Court, in its order dated April 28, 2016, has allowed Indian biopharmaceutical company Biocon and its partner Mylan Pharmaceuticals to continue marketing their breast cancer drug trastuzumab until the next court hearing, on July 21, 2016. Mr Justice Badar Durrez Ahmed and Mr Justice Sanjeev Sachdeva delivered the ruling in the case of Biocon Limited v Roche Products (India) Private Limited & Ors.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

IndiaMart v CDSCO: A test of intermediary liability

31 March 2026 The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.

Asia

Part I: Ozempic goes generic as Novo’s key patent expires

20 March 2026 As the patent protecting semaglutide—the drug that made Novo Nordisk one of Europe's most valuable companies—expires in ten countries, the pressure mounts for prices and market leaders alike.

Asia

AstraZeneca partners with Chinese firm ahead of next obesity race

5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.

More features

Court narrows Mylan’s Copaxone suit but key claims survive

LSPN Awards USA: Meet the judges

Gilead to pay up to $5bn for antibody-drug conjugates push

Closing the women's health gap offers ‘benefits for all’

Bausch reaches deal with competitor over IBS drug generic

European patent offices raise fees

UPC refuses early knockout in Illumina–Element dispute

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

Case report: Biocon’s breast cancer biosimilar gets green light

More on this story

Editor's picks

Editor's picks

More features